SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends
Journal of Renal Injury Prevention · 27.04.2025 · 14 (3) · e38409
DOI: 10.34172/jrip.2025.38409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Renal Injury Prevention, online erschienen am 27.04.2025. Verfasst von Mohammad Memarian und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
The landscape of pulmonary hypertension (PAH) treatment is evolving, with SGLT2 inhibitors being recognized as a potential fourth treatment pathway alongside traditional therapies. Their incorporation into treatment strategies for PAH could represent a significant shift in management approaches.
Zitieren
APA
Memarian, M., & Eskandarian, R. (2025). SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends. Journal of Renal Injury Prevention, 14(3), e38409. https://doi.org/10.34172/jrip.2025.38409
Vancouver
Memarian M, Eskandarian R. SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends. Journal of Renal Injury Prevention. 2025;14(3):e38409. doi:10.34172/jrip.2025.38409
BibTeX
@article{Memarian2025,
author = {Memarian, Mohammad and Eskandarian, Rahimeh},
title = {SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends},
journal = {Journal of Renal Injury Prevention},
year = {2025},
volume = {14},
number = {3},
pages = {e38409},
doi = {10.34172/jrip.2025.38409}
}
EUVIMED